Seer, Inc. (NASDAQ:SEER) CEO Omid Farokhzad Sells 8,068 Shares of Stock

Seer, Inc. (NASDAQ:SEER) CEO Omid Farokhzad sold 8,068 shares of Seer stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $2.24, for a total transaction of $18,072.32. Following the completion of the transaction, the chief executive officer now owns 1,428,217 shares in the company, valued at approximately $3,199,206.08. This represents a 0.56 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Seer Price Performance

Seer stock opened at $2.28 on Thursday. Seer, Inc. has a one year low of $1.51 and a one year high of $2.63. The business has a fifty day moving average of $2.37 and a two-hundred day moving average of $2.07.

Hedge Funds Weigh In On Seer

Several hedge funds have recently bought and sold shares of SEER. Y Intercept Hong Kong Ltd purchased a new position in shares of Seer in the 4th quarter worth $36,000. AQR Capital Management LLC purchased a new position in shares of Seer in the second quarter valued at $30,000. Quadrature Capital Ltd grew its stake in shares of Seer by 301.7% during the third quarter. Quadrature Capital Ltd now owns 57,088 shares of the company’s stock valued at $112,000 after acquiring an additional 42,875 shares in the last quarter. XTX Topco Ltd purchased a new stake in Seer during the 3rd quarter worth approximately $123,000. Finally, Barclays PLC raised its position in shares of Seer by 34.1% in the 3rd quarter. Barclays PLC now owns 64,426 shares of the company’s stock valued at $127,000 after purchasing an additional 16,382 shares in the last quarter. Hedge funds and other institutional investors own 75.20% of the company’s stock.

About Seer

Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.